FDA approves ensitrelvir as first oral antiviral for COVID-19 prevention
On October 8, 2026, the FDA approved ensitrelvir (Xocova) for COVID-19 post-exposure prophylaxis in adults and adolescents aged 12 and older. This is the first oral antiviral for this use in the U.S., shown to reduce symptomatic COVID-19 cases significantly in clinical trials.
Around October 8, 2026, the FDA approved ensitrelvir, marketed as Xocova, as the first oral antiviral for post-exposure prophylaxis (PEP) against COVID-19. This approval represents a new therapeutic option for individuals aged 12 years and older who have been exposed to the virus. By addressing a gap in preventive care, the medication offers a practical strategy for people to protect their health following a potential exposure.
Ensitrelvir works as a main protease inhibitor for SARS-CoV-2, the virus that causes COVID-19. It functions by selectively blocking the main protease enzyme, which the virus requires to replicate itself. The treatment consists of a five-day course, starting with three tablets on the first day and continuing with one tablet daily for the remaining four days. This regimen is intended to suppress viral replication early, reducing the likelihood that an exposure will turn into a symptomatic infection.
The approval was based on data from the Phase 3 SCORPIO-PEP trial, a randomized, double-blind, placebo-controlled study. Participants in the trial were household contacts of people with symptomatic COVID-19, and they began the regimen within 72 hours of the initial patient showing symptoms. The results showed that symptomatic COVID-19 developed in only 2.9% of those taking ensitrelvir, compared to 9.0% in the placebo group. Adverse events were similar between the two groups, and the study recorded no COVID-19-related hospitalizations or deaths.
Beyond the immediate benefits for individuals, the introduction of a preventive oral antiviral has broader significance for public health. Having this option available could change how COVID-19 prevention is managed, particularly for those in high-risk categories. This development may also assist in managing the impact of the virus on chronic health conditions and could potentially lower the incidence of long COVID, which remains a significant concern.
The approval of ensitrelvir suggests new directions for future research into antiviral therapies. The decision by the FDA emphasizes the role of ongoing innovation and the importance of clinical trials in confirming the safety and effectiveness of new treatments. As the global community continues to handle the challenges of the virus, the availability of preventive measures like ensitrelvir serves as a useful tool for public health efforts.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Maria champions local voices and the communities behind the headlines.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
